ISTA seeks bromfenac OK; gets nod for injected hyaluronidase

Irvine, CA-ISTA Pharmaceuticals Inc. is seeking FDA approval of its bromfenac sodium ophthalmic solution 0.1% (Xibrom) for the treatment of ocular inflammation following cataract surgery.

Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.